Transaction Details

Footnotes

The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. | The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). | Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. | The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the number of shares granted based on specific performance metrics of the registrant during the period beginning on January 1, 2024 through December 31, 2025. | Represents shares withheld to cover tax withholding obligations in connection with the vesting of the performance-based restricted stock award.